Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models

Core Insights - Altamira Therapeutics has published significant findings regarding the Zbtb46 mRNA nanoparticles, demonstrating a substantial reduction in tumor growth and potential for long-term remission when combined with anti-PD1 therapies [1][2][3] Group 1: Research Findings - Treatment with ZbtbB46 mRNA nanoparticles resulted in a significant reduction in tumor growth (p<0.0001) [1] - The combination of Zbtb46 mRNA nanoparticles with anti-PD1 immune checkpoint inhibitors showed enhanced tumor control and long-term complete remission in many cases [1][3] - The study highlighted the role of the Zbtb46 gene in tumor angiogenesis and anti-tumor immunity, indicating that enforced expression of Zbtb46 can mitigate pro-tumor microenvironment features [2][3] Group 2: Mechanism and Implications - Zbtb46 is critical for maintaining a healthy tumor microenvironment, as its downregulation leads to dysfunctional vasculature and immunosuppressive conditions [2] - The research suggests that Zbtb46 mRNA nanoparticles can create favorable conditions for anti-PD1 treatments, potentially expanding the patient population that can benefit from these therapies [2][3] - The combination therapy not only improved treatment outcomes but also indicated the development of immunological memory, as mice did not develop new cancers after treatment [3] Group 3: Technology Overview - Altamira's SemaPhore platform is designed for effective mRNA delivery to non-hepatic tissues, utilizing a proprietary peptide for rapid self-assembly into nanoparticles [4] - The SemaPhore technology protects RNA from degradation and facilitates efficient cellular uptake, demonstrating positive outcomes in various disease models [4] Group 4: Company Background - Altamira Therapeutics is focused on developing peptide-based nanoparticle technologies for RNA delivery, with ongoing preclinical programs targeting KRAS-driven cancer and rheumatoid arthritis [5] - The company also holds a significant stake in Altamira Medica AG, which markets Bentrio®, an OTC nasal spray for allergic rhinitis [5]